The quest for vaccines and treatments against COVID-19 has put the CEOs of certain companies, both large and small, on the industry’s radar. The CEOs of J&J, AstraZeneca, Pfizer, Moderna,…
Biologics and New Drug Approvals: The Latest Trends
How are biologics faring in terms of new drug approvals? DCAT Value Chain Insights examines biologic-based APIs approved as new molecular entities by the FDA’s Center for Drug Evaluation and…
What are the latest developments in upstream and downstream bioprocessing? DCAT Value Chain Insights provides a roundup of CDMO/CMO expansions in biomanufacturing and manufacturing for cell and gene therapies. CDMO/CMO…
The Market Impact of COVID-19 on the Pharma Industry
An upcoming DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on companies’ pipelines, product launches, and performance and how…
The Pipeline Contenders: What Drugs Are Making the Mark?
What are the key developments from the large pharmaceutical companies’ pipelines expected for later this year? Which new drugs or additional indications for existing drugs have blockbuster potential? DCAT Value…
The UK and the European Union (EU) are resuming negotiations this week (September 29 to October 2, 2020) for a deal that would define the UK’s future relationship with the…
Industry Perspectives: Low-Volume Drugs and Manufacturing
The rise in the number of orphan-drug approvals and an increase in the development of more targeted therapies with smaller patient populations results in lower-volume drugs. What is the impact…
Pharma Company on the Move: Alnylam Pharmaceuticals
Buoyed by $2 billion in funding by the private equity firm, Blackstone, a $1-billion partnering deal with Regeneron Pharmaceuticals, and potential gains from a possible blockbuster anti-cholesterol drug it has…
The FDA Advises on GMP, Manufacturing and COVID-19
The FDA has issued guidance to advise drug manufacturers how to resume normal manufacturing operations that were impacted by the COVID-19 pandemic, which has caused unusual challenges: employee illness and…
Injectable drugs are assuming a larger role in recent drug approvals and drug development owing to the increase in biologic-based drug development and complexity of APIs, which make injectable delivery…
